JP7617043B2 - tert-ブチル(S)-2-((2S,3R)-1-アミノ-3-ヒドロキシ-1-オキソブタン-2-イル)-1-オキソ-2,5-ジアザスピロ[3.4]オクタン-5-カルボキシレートの固体形態およびそれらを調製する方法 - Google Patents
tert-ブチル(S)-2-((2S,3R)-1-アミノ-3-ヒドロキシ-1-オキソブタン-2-イル)-1-オキソ-2,5-ジアザスピロ[3.4]オクタン-5-カルボキシレートの固体形態およびそれらを調製する方法 Download PDFInfo
- Publication number
- JP7617043B2 JP7617043B2 JP2021576883A JP2021576883A JP7617043B2 JP 7617043 B2 JP7617043 B2 JP 7617043B2 JP 2021576883 A JP2021576883 A JP 2021576883A JP 2021576883 A JP2021576883 A JP 2021576883A JP 7617043 B2 JP7617043 B2 JP 7617043B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- crystalline form
- solid
- peaks
- exemplary embodiment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025001914A JP7858096B2 (ja) | 2019-06-24 | 2025-01-06 | tert-ブチル(S)-2-((2S,3R)-1-アミノ-3-ヒドロキシ-1-オキソブタン-2-イル)-1-オキソ-2,5-ジアザスピロ[3.4]オクタン-5-カルボキシレートの固体形態およびそれらを調製する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962865826P | 2019-06-24 | 2019-06-24 | |
| US62/865,826 | 2019-06-24 | ||
| PCT/US2020/039163 WO2020263847A1 (en) | 2019-06-24 | 2020-06-23 | Solid forms of tert-butyl (s)-2-((2s,3r) -1-amino-3-hydroxy-1-oxobu tan-2-yl)-1-oxo-2, 5-diazaspiro [3.4] octan e-5-carboxylate and methods of preparing them |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025001914A Division JP7858096B2 (ja) | 2019-06-24 | 2025-01-06 | tert-ブチル(S)-2-((2S,3R)-1-アミノ-3-ヒドロキシ-1-オキソブタン-2-イル)-1-オキソ-2,5-ジアザスピロ[3.4]オクタン-5-カルボキシレートの固体形態およびそれらを調製する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022539342A JP2022539342A (ja) | 2022-09-08 |
| JP2022539342A5 JP2022539342A5 (cg-RX-API-DMAC7.html) | 2023-06-30 |
| JP7617043B2 true JP7617043B2 (ja) | 2025-01-17 |
Family
ID=74060350
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021576883A Active JP7617043B2 (ja) | 2019-06-24 | 2020-06-23 | tert-ブチル(S)-2-((2S,3R)-1-アミノ-3-ヒドロキシ-1-オキソブタン-2-イル)-1-オキソ-2,5-ジアザスピロ[3.4]オクタン-5-カルボキシレートの固体形態およびそれらを調製する方法 |
| JP2025001914A Active JP7858096B2 (ja) | 2019-06-24 | 2025-01-06 | tert-ブチル(S)-2-((2S,3R)-1-アミノ-3-ヒドロキシ-1-オキソブタン-2-イル)-1-オキソ-2,5-ジアザスピロ[3.4]オクタン-5-カルボキシレートの固体形態およびそれらを調製する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025001914A Active JP7858096B2 (ja) | 2019-06-24 | 2025-01-06 | tert-ブチル(S)-2-((2S,3R)-1-アミノ-3-ヒドロキシ-1-オキソブタン-2-イル)-1-オキソ-2,5-ジアザスピロ[3.4]オクタン-5-カルボキシレートの固体形態およびそれらを調製する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220267341A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3986399A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7617043B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20260061467A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114364380A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020304001B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021026380A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3144600A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL289198A (cg-RX-API-DMAC7.html) |
| MA (1) | MA56550A (cg-RX-API-DMAC7.html) |
| MX (2) | MX2022000069A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020263847A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI887245B (zh) * | 2019-06-24 | 2025-06-21 | 美商諾雷克斯股份有限公司 | 用於產生二氮雜螺內醯胺化合物之方法及中間物 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014120786A1 (en) | 2013-01-29 | 2014-08-07 | Naurex, Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| WO2017201283A1 (en) | 2016-05-19 | 2017-11-23 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| WO2020263848A1 (en) | 2019-06-24 | 2020-12-30 | Naurex Inc. | Processes and intermediates for producing diazaspiro lactam compounds |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0323204D0 (en) * | 2003-10-03 | 2003-11-05 | Novartis Ag | Organic compounds |
| ES2416354T3 (es) * | 2005-06-21 | 2013-07-31 | Ajinomoto Co., Inc. | Cristal de derivado de fenilalanina, método de producción del mismo y uso del mismo |
| MX2011003015A (es) * | 2008-09-18 | 2011-11-18 | Univ Northwestern | Moduladores del receptor de n-metil-d-aspartato, y usos de los mismos. |
| CA2898861C (en) * | 2013-01-29 | 2021-07-20 | Naurex, Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| TWI738748B (zh) * | 2016-03-28 | 2021-09-11 | 日商武田藥品工業有限公司 | 2-[(2s)-1-氮雜雙環[2.2.2]辛-2-基]-6-(3-甲基-1h-吡唑-4-基)噻吩并[3,2-d]嘧啶-4(3h)-酮半水合物之晶形 |
-
2020
- 2020-06-23 BR BR112021026380A patent/BR112021026380A2/pt unknown
- 2020-06-23 EP EP20832010.1A patent/EP3986399A4/en active Pending
- 2020-06-23 JP JP2021576883A patent/JP7617043B2/ja active Active
- 2020-06-23 MA MA056550A patent/MA56550A/fr unknown
- 2020-06-23 US US17/621,907 patent/US20220267341A1/en active Pending
- 2020-06-23 KR KR1020267012575A patent/KR20260061467A/ko active Pending
- 2020-06-23 CN CN202080059974.0A patent/CN114364380A/zh active Pending
- 2020-06-23 MX MX2022000069A patent/MX2022000069A/es unknown
- 2020-06-23 WO PCT/US2020/039163 patent/WO2020263847A1/en not_active Ceased
- 2020-06-23 AU AU2020304001A patent/AU2020304001B2/en active Active
- 2020-06-23 KR KR1020227002351A patent/KR102958083B1/ko active Active
- 2020-06-23 CA CA3144600A patent/CA3144600A1/en active Pending
-
2021
- 2021-12-21 IL IL289198A patent/IL289198A/en unknown
-
2022
- 2022-01-03 MX MX2025002579A patent/MX2025002579A/es unknown
-
2025
- 2025-01-06 JP JP2025001914A patent/JP7858096B2/ja active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014120786A1 (en) | 2013-01-29 | 2014-08-07 | Naurex, Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| WO2017201283A1 (en) | 2016-05-19 | 2017-11-23 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| WO2020263848A1 (en) | 2019-06-24 | 2020-12-30 | Naurex Inc. | Processes and intermediates for producing diazaspiro lactam compounds |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114364380A (zh) | 2022-04-15 |
| JP2022539342A (ja) | 2022-09-08 |
| WO2020263847A1 (en) | 2020-12-30 |
| MX2025002579A (es) | 2025-04-02 |
| US20220267341A1 (en) | 2022-08-25 |
| MA56550A (fr) | 2022-04-27 |
| EP3986399A4 (en) | 2023-06-07 |
| AU2020304001A1 (en) | 2022-01-27 |
| EP3986399A1 (en) | 2022-04-27 |
| CA3144600A1 (en) | 2020-12-30 |
| AU2020304001B2 (en) | 2026-04-09 |
| IL289198A (en) | 2022-02-01 |
| MX2022000069A (es) | 2022-05-24 |
| KR20260061467A (ko) | 2026-05-06 |
| KR20220061088A (ko) | 2022-05-12 |
| JP7858096B2 (ja) | 2026-05-13 |
| BR112021026380A2 (pt) | 2022-05-10 |
| JP2025069143A (ja) | 2025-04-30 |
| KR102958083B1 (ko) | 2026-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2970123B1 (en) | Salt of omecamtiv mecarbil and process for preparing salt | |
| JP5635181B2 (ja) | ニトロイミダゾール系化合物、その製造方法および用途 | |
| JP7858096B2 (ja) | tert-ブチル(S)-2-((2S,3R)-1-アミノ-3-ヒドロキシ-1-オキソブタン-2-イル)-1-オキソ-2,5-ジアザスピロ[3.4]オクタン-5-カルボキシレートの固体形態およびそれらを調製する方法 | |
| US11584715B2 (en) | Crystalline form of sofpironium bromide and preparation method thereof | |
| JP2026012715A (ja) | 3-(5-フルオロベンゾフラン-3-イル)-4-(5-メチル-5H-[1,3]ジオキソロ[4,5-f]インドール-7-イル)ピロール-2,5-ジオンの固体形態 | |
| JP2025533955A (ja) | (2s,5r)-5-(2-クロロフェニル)-1-(2’-メトキシ-[1,1’-ビフェニル]-4-カルボニル)ピロリジン-2-カルボン酸の多形およびその調製プロセス | |
| EA044016B1 (ru) | Твердые формы трет-бутил(s)-2-((2s,3r)-1-амино-3-гидрокси-1-оксобутан-2-ил)-1-оксо-2,5-диазаспиро[3.4]октан-5-карбоксилата и способы их получения | |
| EP2459520A1 (en) | Crystalline forms of fesoterodine fumarate and fesoterodine base | |
| HK40068368B (en) | Crystalline form of sofpironium bromide and preparation method thereof | |
| TW202541790A (zh) | 馬立馬司他之結晶多晶型、馬立馬司他之非晶質型、其製備的製程、包含其之藥物組成物及其用途 | |
| CA2989364C (en) | Process for the preparation of enclomiphene citrate having needle shaped crystal habit. | |
| HK40068368A (en) | Crystalline form of sofpironium bromide and preparation method thereof | |
| CA2902436C (en) | Salt of omecamtiv mecarbil and process for preparing salt | |
| TW202332440A (zh) | 神經激肽-1拮抗劑前藥化合物的晶型 | |
| HK40035144B (en) | Preparation process of two compounds | |
| HK40037540B (en) | Crystal forms and production methods thereof | |
| HK40037540A (en) | Crystal forms and production methods thereof | |
| HK1218544B (en) | Salt of omecamtiv mecarbil and process for preparing salt | |
| JP2012500192A (ja) | 1−イソプロピル−4−{[4−(テトラヒドロ−2h−ピラン−4−イルオキシ)フェニル]カルボニル}ヘキサヒドロ−1h−1,4−ジアゼピンの塩およびその調製方法 | |
| HK1159095A (en) | Synthesis and novel salt forms of (r)-5-(e)-2-(pyrrolidin-3-ylvinyl)pyrimidine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230622 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230622 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240520 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240815 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20241202 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250106 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7617043 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |